Blueprint Medicines (NASDAQ:BPMC) Given Buy Rating at

2 days ago · One equities research analyst has rated the stock with a sell rating, seven have …

CouponFollow Extension

$1.29
OFF

Blueprint Medicines (BPMC) Upgraded To Strong Buy: What Does …

1 week from now

Oct 21, 2024 · This cancer drug developer is expected to earn -$1.29 per share for the fiscal …

nasdaq.com

$56.74
OFF

Blueprint Medicines (NASDAQ:BPMC) Given “Buy” Rating At …

1 week from now

Nov 3, 2024 · Blueprint Medicines has a 1 year low of $56.74 and a 1 year high of $121.90. …

defenseworld.net

$115
OFF

Blueprint Medicines (BPMC) Stock Price, News & Analysis

1 week from now

3 days ago · Blueprint Medicines (BPMC) raised $115 million in an initial public offering on …

marketbeat.com

100%
OFF

BLUEPRINT CAFE LOUNGE - Updated August 2024 - Yelp

1 week from now

Welcome to Sunny Vegan Cafe! We specialize in 100% vegan meals and delectable desserts. …

yelp.com

FAQs about Blueprint Medicines (NASDAQ:BPMC) Given Buy Rating at Coupon?

Is blueprint medicines a good stock to buy?

Blueprint Medicines has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 7 buy ratings, 7 hold ratings, and 1 sell rating. According to analysts' consensus price target of $72.68, Blueprint Medicines has a forecasted upside of 66.7% from its current price of $43.61. ...

Should you buy blueprint medicines (BPMC) stock?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 1 sell rating, 7 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BPMC shares. ...

What makes blueprint medicines a good company?

Andrew Fein’s rating is based on several compelling factors related to Blueprint Medicines’ innovative approaches and pipeline potential. The company has highlighted significant growth opportunities beyond its existing treatments, particularly through its focus on mast cell-related diseases. ...

Who owns blueprint medicines?

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA. If you thought the SVB meltdown was bad… watch out. ...

How much does blueprint medicines make?

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $2.64 billion and generates $204.04 million in revenue each year. The biotechnology company earns $-557,520,000.00 in net income (profit) each year or ($9.35) on an earnings per share basis. ...

Will blueprint medicines open the door to larger markets?

This program has the potential to open the door to larger markets, including treatments for urticaria and asthma. We look forward to more details on Blueprint Medicines’ plans during their scientific seminar later today and expect Phase 1 trial data in early 2025. ...